Abstract
Many individual variables are predictive of an increased risk of mortality and morbidity in heart failure. These include a range of data from patient demographics, clinical findings, comorbidities and invasive and noninvasive parameters. Some of these markers, for example the B-type natriuretic peptides, have been identified as independently predictive in large, robust, multivariable analyses. However, many markers have had less vigorous scrutiny and were identified in small cohorts after only univariate or limited multivariable analyses. Recently, cardiac troponins have emerged as potential biomarkers for patients with heart failure. In this article, we consider the utility of cardiac troponins in heart failure and propose what role they may play in improving the risk stratification of this disease.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.